ACT Advisors
RANI icon

ACT Advisors’s Rani Therapeutics RANI Stock Holding History

ACT Advisors’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.6K Sell
14,701
-105
-0.7% -$84 ﹤0.01% 82
2026
Q2 		$11.3K Hold
14,806
– – ﹤0.01% 80
2026
Q1 		$10.9K Sell
14,806
-1,256
-8% -$1.6K ﹤0.01% 75
2025
Q4 		$21.7K Buy
16,062
+1,256
+8% +$1.9K 0.01% 62
2025
Q3 		$7.4K Buy
+14,806
New +$7.72K ﹤0.01% 72

Other funds holding RANI

Kestra Private Wealth Services
Kestra Private Wealth Services Austin, Texas $9.37B AUM 22.72% 1-Year Est. Return
CWA Asset Management Group
CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return
Well Done LLC
Well Done LLC Holland, Michigan $732M AUM 14.62% 1-Year Est. Return
Traphagen Investment Advisors
Traphagen Investment Advisors Oradell, New Jersey $1.46B AUM 14.92% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Prime Capital Investment Advisors
Prime Capital Investment Advisors Overland Park, Kansas $10.2B AUM 17.74% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57.1B AUM 43.46% 1-Year Est. Return
Glass Jacobson Investment Advisors
Glass Jacobson Investment Advisors Owings Mills, Maryland $326M AUM 13.52% 1-Year Est. Return

ACT Advisors's RANI Position: Q3 2026 in Review

ACT Advisors reduced its Rani Therapeutics (RANI) stake by 0.71% in Q3 2026, selling an estimated $84 and leaving 14,701 shares worth $11.6K. The position accounts for ﹤0.01% of the portfolio, ranked #82.

ACT Advisors first reported a position in RANI in Q3 2025 and has held it in 5 quarters since. The position peaked at $21.7K in Q4 2025. 12 funds tracked by Wall St. Rank hold RANI as of Q3 2026.

  • ACT Advisors held 14,701 shares of Rani Therapeutics worth $11.6K as of Q3 2026.
  • ACT Advisors sold 105 Rani Therapeutics shares in Q3 2026, an estimated $84.
  • Rani Therapeutics made up ﹤0.01% of ACT Advisors's portfolio in Q3 2026, its #82 holding.
  • ACT Advisors first reported a position in Rani Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • ACT Advisors's Rani Therapeutics position peaked at $21.7K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held Rani Therapeutics as of Q3 2026.

Based on ACT Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.